Dual character of Toll-like receptor signaling: Pro-tumorigenic effects and anti-tumor functions

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 2, 2013, Pages 144-154

  Yu, Li ^a   Wang, Liantang ^a   Chen, Shangwu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Anti tumor immunity; Pro tumorigenic effects; Toll like receptor; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; DOXORUBICIN; HIGH MOBILITY GROUP B1 PROTEIN; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; KRESTIN; LOXORIBINE; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; POLYADENYLIC POLYURIDYLIC ACID; POLYINOSINIC POLYCYTIDYLIC ACID; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 2 AGONIST; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TOLL LIKE RECEPTOR AGONIST; TRASTUZUMAB; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; DISEASE ACTIVITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INTERNALIZATION; LUNG TUMOR; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR IMMUNOLOGY;

ANIMALS; APOPTOSIS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 84872199330     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.10.006     Document Type: Review

References (125)

1. Anderson K.V., Bokla L., Nusslein-Volhard C. Establishment of dorsal-ventral polarity in the Drosophila embryo: the induction of polarity by the Toll gene product. Cell 1985, 42:791-798.
2. Lemaitre B., Nicolas E., Michaut L., Reichhart J.M., Hoffmann J.A. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86:973-983.
3. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., Birdwell D., Alejos E., Silva M., Galanos C., Freudenberg M., Ricciardi-Castagnoli P., Layton B., Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
4. Scaffidi P., Misteli T., Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002, 418:191-195.
5. Yu L., Wang L., Chen S. Exogenous or endogenous Toll-like receptor ligands: which is the MVP in tumorigenesis. Cell. Mol. Life Sci. 2012, 69:935-949.
6. O'Neill L.A., Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 2007, 7:353-364.
7. Akira S., Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4:499-511.
8. Polk D.B., Peek R.M. Helicobacter pylori: gastric cancer and beyond. Nat. Rev. Cancer 2010, 10:403-414.
9. Karin M., Lawrence T., Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006, 124:823-835.
10. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189:12-19.
11. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
12. Fukata M., Chen A., Vamadevan A.S., Cohen J., Breglio K., Krishnareddy S., Hsu D., Xu R., Harpaz N., Dannenberg A.J., Subbaramaiah K., Cooper H.S., Itzkowitz S.H., Abreu M.T. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007, 133:1869-1881.
13. Yu L.X., Yan H.X., Liu Q., Yang W., Wu H.P., Dong W., Tang L., Lin Y., He Y.Q., Zou S.S., Wang C., Zhang H.L., Cao G.W., Wu M.C., Wang H.Y. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology 2010, 52:1322-1333.
14. Rakoff-Nahoum S., Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007, 317:124-127.
15. Lowe E.L., Crother T.R., Rabizadeh S., Hu B., Wang H., Chen S., Shimada K., Wong M.H., Michelsen K.S., Arditi M. Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One 2010, 5:e13027.
16. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M.C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F.J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J.P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., Andre F., Delaloge S., Tursz T., Kroemer G., Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 2007, 13:1050-1059.
17. He W., Liu Q., Wang L., Chen W., Li N., Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol. 2007, 44:2850-2859.
18. Huang B., Zhao J., Li H., He K.L., Chen Y., Chen S.H., Mayer L., Unkeless J.C., Xiong H. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005, 65:5009-5014.
19. Mittal D., Saccheri F., Venereau E., Pusterla T., Bianchi M.E., Rescigno M. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 2010, 29:2242-2252.
20. Lee C.H., Wu C.L., Shiau A.L. Toll-like receptor 4 signaling promotes tumor growth. J. Immunother. 2010, 33:73-82.
21. Nischalke H.D., Coenen M., Berger C., Aldenhoff K., Muller T., Berg T., Kramer B., Korner C., Odenthal M., Schulze F., Grunhage F., Nattermann J., Sauerbruch T., Spengler U. The toll-like receptor 2 (TLR2) -196 to -174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int. J. Cancer 2012, 130:1470-1475.
22. Hold G.L., Rabkin C.S., Chow W.H., Smith M.G., Gammon M.D., Risch H.A., Vaughan T.L., McColl K.E., Lissowska J., Zatonski W., Schoenberg J.B., Blot W.J., Mowat N.A., Fraumeni J.F., El-Omar E.M. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007, 132:905-912.
23. Ohara T., Morishita T., Suzuki H., Hibi T. Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int. J. Mol. Med. 2006, 18:59-63.
24. Fukata M., Shang L., Santaolalla R., Sotolongo J., Pastorini C., Espana C., Ungaro R., Harpaz N., Cooper H.S., Elson G., Kosco-Vilbois M., Zaias J., Perez M.T., Mayer L., Vamadevan A.S., Lira S.A., Abreu M.T. Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm. Bowel Dis. 2011, 17:1464-1473.
25. Wang E.L., Qian Z.R., Nakasono M., Tanahashi T., Yoshimoto K., Bando Y., Kudo E., Shimada M., Sano T. High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br. J. Cancer 2010, 102:908-915.
26. Cammarota R., Bertolini V., Pennesi G., Bucci E.O., Gottardi O., Garlanda C., Laghi L., Barberis M.C., Sessa F., Noonan D.M., Albini A. The tumor microenviroment of colo-rectal cancer; stromal TLR-4 expression as a potential prognostic marker. J. Transl. Med. 2010, 8:112.
27. Brugge J., Hung M.C., Mills G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007, 12:104-107.
28. Szczepanski M.J., Czystowska M., Szajnik M., Harasymczuk M., Boyiadzis M., Kruk-Zagajewska A., Szyfter W., Zeromski J., Whiteside T.L. Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009, 69:3105-3113.
29. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., Visintin I., Rutherford T., Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006, 66:3859-3868.
30. Doan H.Q., Bowen K.A., Jackson L.A., Evers B.M. Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res. 2009, 29:2473-2478.
31. Hsu R.Y., Chan C.H., Spicer J.D., Rousseau M.C., Giannias B., Rousseau S., Ferri L.E. LPS-induced TLR4 signaling in human colorectal cancer cells increases {beta}1 integrin-mediated cell adhesion and liver metastasis. Cancer Res. 2011, 71:1989-1998.
32. Hernandez Y., Sotolongo J., Breglio K., Conduah D., Chen A., Xu R., Hsu D., Ungaro R., Hayes L.A., Pastorini C., Abreu M.T., Fukata M. The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol. 2010, 10:82.
33. Bao H., Lu P., Li Y., Wang L., Li H., He D., Yang Y., Zhao Y., Yang L., Wang M., Yi Q., Cai Z. Triggering of toll-like receptor-4 in human multiple myeloma cells promotes proliferation and alters cell responses to immune and chemotherapy drug attack. Cancer Biol. Ther. 2011, 11:58-67.
34. Zhou B., Zhou H., Ling S., Guo D., Yan Y., Zhou F., Wu Y. Activation of PAR2 or/and TLR4 promotes SW620 cell proliferation and migration via phosphorylation of ERK1/2. Oncol. Rep. 2011, 25:503-511.
35. Xu H., Wu Q., Dang S., Jin M., Xu J., Cheng Y., Pan M., Wu Y., Zhang C., Zhang Y. Alteration of CXCR7 expression mediated by TLR4 promotes tumor cell proliferation and migration in human colorectal carcinoma. PLoS One 2011, 6:e27399.
36. Szajnik M., Szczepanski M.J., Czystowska M., Elishaev E., Mandapathil M., Nowak-Markwitz E., Spaczynski M., Whiteside T.L. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer. Oncogene 2009, 28:4353-4363.
37. Yang H., Zhou H., Feng P., Zhou X., Wen H., Xie X., Shen H., Zhu X. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J. Exp. Clin. Cancer Res. 2010, 29:92.
38. Hua D., Liu M.Y., Cheng Z.D., Qin X.J., Zhang H.M., Chen Y., Qin G.J., Liang G., Li J.N., Han X.F., Liu D.X. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol. Immunol. 2009, 46:2876-2884.
39. Sun Z., Luo Q., Ye D., Chen W., Chen F. Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis. Mol. Cancer 2012, 11:33.
40. Liao S.J., Zhou Y.H., Yuan Y., Li D., Wu F.H., Wang Q., Zhu J.H., Yan B., Wei J.J., Zhang G.M., Feng Z.H. Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes alphavbeta3-mediated adhesion and invasive migration. Breast Cancer Res. Treat. 2012, 133:853-863.
41. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., Nguyen M., Olsson A., Nawroth P.P., Bierhaus A., Varki N., Kronenberg M., Freeze H.H., Srikrishna G. RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008, 29:2035-2043.
42. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., Shibuya M., Akira S., Aburatani H., Maru Y. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat. Cell Biol. 2008, 10:1349-1355.
43. Voelcker V., Gebhardt C., Averbeck M., Saalbach A., Wolf V., Weih F., Sleeman J., Anderegg U., Simon J. Hyaluronan fragments induce cytokine and metalloprotease upregulation in human melanoma cells in part by signalling via TLR4. Exp. Dermatol. 2008, 17:100-107.
44. Riddell J.R., Bshara W., Moser M.T., Spernyak J.A., Foster B.A., Gollnick S.O. Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature. Cancer Res. 2011, 71:1637-1646.
45. Nunez N.G., Andreani V., Crespo M.I., Nocera D.A., Breser M.L., Moron G., Dejager L., Libert C., Rivero V., Maccioni M. IFNbeta produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response. Cancer Res. 2012, 72:592-603.
46. Gatti G., Quintar A.A., Andreani V., Nicola J.P., Maldonado C.A., Masini-Repiso A.M., Rivero V.E., Maccioni M. Expression of Toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate 2009, 69:1387-1397.
47. Yusuf N., Nasti T.H., Long J.A., Naseemuddin M., Lucas A.P., Xu H., Elmets C.A. Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res. 2008, 68:615-622.
48. Chuang H.C., Huang C.C., Chien C.Y., Chuang J.H. Toll-like receptor 3-mediated tumor invasion in head and neck cancer. Oral Oncol. 2012, 48:226-232.
49. Matijevic T., Pavelic J. The dual role of TLR3 in metastatic cell line. Clin. Exp. Metastasis 2011, 28:701-712.
50. Tanaka J., Sugimoto K., Shiraki K., Tameda M., Kusagawa S., Nojiri K., Beppu T., Yoneda K., Yamamoto N., Uchida K., Kojima T., Takei Y. Functional cell surface expression of Toll-like receptor 9 promotes cell proliferation and survival in human hepatocellular carcinomas. Int. J. Oncol. 2010, 37:805-814.
51. Merrell M.A., Ilvesaro J.M., Lehtonen N., Sorsa T., Gehrs B., Rosenthal E., Chen D., Shackley B., Harris K.W., Selander K.S. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol. Cancer Res. 2006, 4:437-447.
52. Ilvesaro J.M., Merrell M.A., Li L., Wakchoure S., Graves D., Brooks S., Rahko E., Jukkola-Vuorinen A., Vuopala K.S., Harris K.W., Selander K.S. Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Mol. Cancer Res. 2008, 6:1534-1543.
53. Berger R., Fiegl H., Goebel G., Obexer P., Ausserlechner M., Doppler W., Hauser-Kronberger C., Reitsamer R., Egle D., Reimer D., Muller-Holzner E., Jones A., Widschwendter M. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 2010, 101:1059-1066.
54. Ren T., Wen Z.K., Liu Z.M., Liang Y.J., Guo Z.L., Xu L. Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol. Ther. 2007, 6:1704-1709.
55. Xu L., Zhou Y., Liu Q., Luo J.M., Qing M., Tang X.Y., Yao X.S., Wang C.H., Wen Z.K. CXCR4/SDF-1 pathway is crucial for TLR9 agonist enhanced metastasis of human lung cancer cell. Biochem. Biophys. Res. Commun. 2009, 382:571-576.
56. Ilvesaro J.M., Merrell M.A., Swain T.M., Davidson J., Zayzafoon M., Harris K.W., Selander K.S. Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate 2007, 67:774-781.
57. Jego G., Bataille R., Geffroy-Luseau A., Descamps G., Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 2006, 20:1130-1137.
58. Di J.M., Pang J., Sun Q.P., Zhang Y., Fang Y.Q., Liu X.P., Zhou J.H., Ruan X.X., Gao X. Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF-kappaB in prostate cancer cells. Mol. Biol. Rep. 2010, 37:1849-1855.
59. Di J.M., Pang J., Pu X.Y., Zhang Y., Liu X.P., Fang Y.Q., Ruan X.X., Gao X. Toll-like receptor 9 agonists promote IL-8 and TGF-beta1 production via activation of nuclear factor kappaB in PC-3 cells. Cancer Genet. Cytogenet. 2009, 192:60-67.
60. Vaisanen M.R., Vaisanen T., Jukkola-Vuorinen A., Vuopala K.S., Desmond R., Selander K.S., Vaarala M.H. Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors. Prostate 2010, 70:817-824.
61. Leng L., Jiang T., Zhang Y. TLR9 expression is associated with prognosis in patients with glioblastoma multiforme. J. Clin. Neurosci. 2012, 19:75-80.
62. Swann J.B., Vesely M.D., Silva A., Sharkey J., Akira S., Schreiber R.D., Smyth M.J. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:652-656.
63. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
64. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., Kohlhammer H., Xu W., Yang Y., Zhao H., Shaffer A.L., Romesser P., Wright G., Powell J., Rosenwald A., Muller-Hermelink H.K., Ott G., Gascoyne R.D., Connors J.M., Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R., Cook J.R., Weisenburger D.D., Chan W.C., Staudt L.M. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
65. Zhang Y., Luo F., Cai Y., Liu N., Wang L., Xu D., Chu Y. TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J. Immunol. 2011, 186:1963-1969.
66. Curtin J.F., Liu N., Candolfi M., Xiong W., Assi H., Yagiz K., Edwards M.R., Michelsen K.S., Kroeger K.M., Liu C., Muhammad A.K., Clark M.C., Arditi M., Comin-Anduix B., Ribas A., Lowenstein P.R., Castro M.G. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med. 2009, 6:e10.
67. Do K.N., Fink L.N., Jensen T.E., Gautier L., Parlesak A. TLR2 controls intestinal carcinogen detoxication by CYP1A1. PLoS One 2012, 7:e32309.
68. Lu H., Yang Y., Gad E., Inatsuka C., Wenner C.A., Disis M.L., Standish L.J. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin. Cancer Res. 2011, 17:6742-6753.
69. Oldford S.A., Haidl I.D., Howatt M.A., Leiva C.A., Johnston B., Marshall J.S. A critical role for mast cells and mast cell-derived IL-6 in TLR2-mediated inhibition of tumor growth. J. Immunol. 2010, 185:7067-7076.
70. Yang H.Z., Cui B., Liu H.Z., Mi S., Yan J., Yan H.M., Hua F., Lin H., Cai W.F., Xie W.J., Lv X.X., Wang X.X., Xin B.M., Zhan Q.M., Hu Z.W. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 2009, 4:e6520.
71. Huang B., Zhao J., Shen S., Li H., He K.L., Shen G.X., Mayer L., Unkeless J., Li D., Yuan Y., Zhang G.M., Xiong H., Feng Z.H. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res. 2007, 67:4346-4352.
72. Xie W., Huang Y., Xie W., Guo A., Wu W. Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cells. PLoS One 2010, 5:e10850.
73. Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., Luo J.L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
74. West X.Z., Malinin N.L., Merkulova A.A., Tischenko M., Kerr B.A., Borden E.C., Podrez E.A., Salomon R.G., Byzova T.V. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature 2010, 467:972-976.
75. Chin A.I., Miyahira A.K., Covarrubias A., Teague J., Guo B., Dempsey P.W., Cheng G. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 2010, 70:2595-2603.
76. Luo Q., Hu S., Yan M., Sun Z., Chen W., Chen F. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo. Int. J. Biochem. Cell Biol. 2012, 44:1266-1275.
77. Akazawa T., Ebihara T., Okuno M., Okuda Y., Shingai M., Tsujimura K., Takahashi T., Ikawa M., Okabe M., Inoue N., Okamoto-Tanaka M., Ishizaki H., Miyoshi J., Matsumoto M., Seya T. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:252-257.
78. Salaun B., Coste I., Rissoan M.C., Lebecque S.J., Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 2006, 176:4894-4901.
79. Shime H., Matsumoto M., Oshiumi H., Tanaka S., Nakane A., Iwakura Y., Tahara H., Inoue N., Seya T. Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2066-2071.
80. Wu C.Y., Yang H.Y., Monie A., Ma B., Tsai H.H., Wu T.C., Hung C.F. Intraperitoneal administration of poly(I:C) with polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. Cancer Immunol. Immunother. 2011, 60:1085-1096.
81. Nicodemus C.F., Wang L., Lucas J., Varghese B., Berek J.S. Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am. J. Obstet. Gynecol. 2010, 202:e601-e608. (608).
82. Salem M.L., Kadima A.N., Cole D.J., Gillanders W.E. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 2005, 28:220-228.
83. Shojaei H., Oberg H.H., Juricke M., Marischen L., Kunz M., Mundhenke C., Gieseler F., Kabelitz D., Wesch D. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res. 2009, 69:8710-8717.
84. Laplanche A., Alzieu L., Delozier T., Berlie J., Veyret C., Fargeot P., Luboinski M., Lacour J. Polyadenylic-polyuridylic acid plus locoregional radiotherapy versus chemotherapy with CMF in operable breast cancer: a 14year follow-up analysis of a randomized trial of the Federation Nationale des Centres de Lutte contre le Cancer (FNCLCC). Breast Cancer Res. Treat. 2000, 64:189-191.
85. Jeung H.C., Moon Y.W., Rha S.Y., Yoo N.C., Roh J.K., Noh S.H., Min J.S., Kim B.S., Chung H.C. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann. Oncol. 2008, 19:520-526.
86. Paone A., Starace D., Galli R., Padula F., De Cesaris P., Filippini A., Ziparo E., Riccioli A. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008, 29:1334-1342.
87. Harashima N., Inao T., Imamura R., Okano S., Suda T., Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol. Immunother. 2011, 61:667-676.
88. Guo Z., Chen L., Zhu Y., Zhang Y., He S., Qin J., Tang X., Zhou J., Wei Y. Double-stranded RNA-induced TLR3 activation inhibits angiogenesis and triggers apoptosis of human hepatocellular carcinoma cells. Oncol. Rep. 2012, 27:396-402.
89. Matijevic T., Marjanovic M., Pavelic J. Functionally active toll-like receptor 3 on human primary and metastatic cancer cells. Scand. J. Immunol. 2009, 70:18-24.
90. Nomi N., Kodama S., Suzuki M. Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol. Rep. 2010, 24:225-231.
91. Sun R., Zhang Y., Lv Q., Liu B., Jin M., Zhang W., He Q., Deng M., Liu X., Li G., Li Y., Zhou G., Xie P., Xie X., Hu J., Duan Z. Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform alpha (TAP63alpha). J. Biol. Chem. 2011, 286:15918-15928.
92. Jiang Q., Wei H., Tian Z. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008, 8:12.
93. Zhang Y., Sun R., Liu B., Deng M., Zhang W., Li Y., Zhou G., Xie P., Li G., Hu J. TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4. Cancer Biol. Ther. 2009, 8:1826-1830.
94. Cai Z., Sanchez A., Shi Z., Zhang T., Liu M., Zhang D. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 2011, 71:2466-2475.
95. Rhee S.H., Im E., Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008, 135:518-528.
96. Garaude J., Kent A., van Rooijen N., Blander J.M. Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci. Transl. Med. 2012, 4. (120ra116).
97. Weiner G.J., Liu H.M., Wooldridge J.E., Dahle C.E., Krieg A.M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:10833-10837.
98. Shirota H., Klinman D.M. CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity. Cancer Immunol. Immunother. 2011, 60:659-669.
99. Hamzah J., Altin J.G., Herringson T., Parish C.R., Hammerling G.J., O'Donoghue H., Ganss R. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J. Immunol. 2009, 183:1091-1098.
100. Leonard J.P., Link B.K., Emmanouilides C., Gregory S.A., Weisdorf D., Andrey J., Hainsworth J., Sparano J.A., Tsai D.E., Horning S., Krieg A.M., Weiner G.J. Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin. Cancer Res. 2007, 13:6168-6174.
101. Manegold C., van Zandwijk N., Szczesna A., Zatloukal P., Au J.S., Blasinska-Morawiec M., Serwatowski P., Krzakowski M., Jassem J., Tan E.H., Benner R.J., Ingrosso A., Meech S.J., Readett D., Thatcher N. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann. Oncol. 2012, 23:72-77.
102. Brignole C., Marimpietri D., Di Paolo D., Perri P., Morandi F., Pastorino F., Zorzoli A., Pagnan G., Loi M., Caffa I., Erminio G., Haupt R., Gambini C., Pistoia V., Ponzoni M. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res. 2010, 70:9816-9826.
103. Kuninaka N., Kurata M., Yamamoto K., Suzuki S., Umeda S., Kirimura S., Arai A., Nakagawa Y., Suzuki K., Kitagawa M. Expression of Toll-like receptor 9 in bone marrow cells of myelodysplastic syndromes is down-regulated during transformation to overt leukemia. Exp. Mol. Pathol. 2010, 88:293-298.
104. Ahn M.Y., Kwon S.M., Cheong H.H., Park J.H., Lee J., Min S.K., Ahn S.G., Yoon J.H. Toll-like receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J. Oral Pathol. Med. 2012, 41:540-546.
105. Smits E.L., Ponsaerts P., Berneman Z.N., Van Tendeloo V.F. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist 2008, 13:859-875.
106. Azuma M., Sawahata R., Akao Y., Ebihara T., Yamazaki S., Matsumoto M., Hashimoto M., Fukase K., Fujimoto Y., Seya T. The peptide sequence of diacyl lipopeptides determines dendritic cell TLR2-mediated NK activation. PLoS One 2010, 5.
107. Akazawa T., Inoue N., Shime H., Kodama K., Matsumoto M., Seya T. Adjuvant engineering for cancer immunotherapy: development of a synthetic TLR2 ligand with increased cell adhesion. Cancer Sci. 2010, 101:1596-1603.
108. Yamazaki S., Okada K., Maruyama A., Matsumoto M., Yagita H., Seya T. TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo. PLoS One 2011, 6:e18833.
109. Lundberg A., Wikberg L.A., Ilonen J., Vaarala O., Bottcher M.F. Lipopolysaccharide-induced immune responses in relation to the TLR4(Asp299Gly) gene polymorphism. Clin. Vaccine Immunol. 2008, 15:1878-1883.
110. Lin A.C., Dissanayake D., Dhanji S., Elford A.R., Ohashi P.S. Different toll-like receptor stimuli have a profound impact on cytokines required to break tolerance and induce autoimmunity. PLoS One 2011, 6:e23940.
111. Bogunovic D., Manches O., Godefroy E., Yewdall A., Gallois A., Salazar A.M., Marie I., Levy D.E., Bhardwaj N. TLR4 engagement during TLR3-induced proinflammatory signaling in dendritic cells promotes IL-10-mediated suppression of antitumor immunity. Cancer Res. 2011, 71:5467-5476.
112. Galli R., Starace D., Busa R., Angelini D.F., Paone A., De Cesaris P., Filippini A., Sette C., Battistini L., Ziparo E., Riccioli A. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J. Immunol. 2010, 184:6658-6669.
113. Wei J.J., Song C.W., Sun L.C., Yuan Y., Li D., Yan B., Liao S.J., Zhu J.H., Wang Q., Zhang G.M., Feng Z.H. SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells. Cancer Immunol. Immunother. 2012, 61:303-312.
114. Pulko V., Liu X., Krco C.J., Harris K.J., Frigola X., Kwon E.D., Dong H. TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination. J. Immunol. 2009, 183:3634-3641.
115. Conforti R., Ma Y., Morel Y., Paturel C., Terme M., Viaud S., Ryffel B., Ferrantini M., Uppaluri R., Schreiber R., Combadiere C., Chaput N., Andre F., Kroemer G., Zitvogel L. Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands. Cancer Res. 2010, 70:490-500.
116. Chiron D., Pellat-Deceunynck C., Amiot M., Bataille R., Jego G. TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J. Immunol. 2009, 182:4471-4478.
117. Xie L., Pries R., Kesselring R., Wulff S., Wollenberg B. Head and neck cancer triggers the internalization of TLR3 in natural killer cells. Int. J. Mol. Med. 2007, 20:493-499.
118. van Zoelen M.A., Yang H., Florquin S., Meijers J.C., Akira S., Arnold B., Nawroth P.P., Bierhaus A., Tracey K.J., van der Poll T. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock 2009, 31:280-284.
119. McCartney S., Vermi W., Gilfillan S., Cella M., Murphy T.L., Schreiber R.D., Murphy K.M., Colonna M. Distinct and complementary functions of MDA5 and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J. Exp. Med. 2009, 206:2967-2976.
120. Tano T., Okamoto M., Kan S., Nakashiro K.I., Shimodaira S., Yamashita N., Kawakami Y., Hamakawa H. Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines. Oral Oncol. 2012, 48:678-685.
121. Song E.J., Kang M.J., Kim Y.S., Kim S.M., Lee S.E., Kim C.H., Kim D.J., Park J.H. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int. J. Mol. Med. 2011, 28:115-119.
122. Sfondrini L., Rossini A., Besusso D., Merlo A., Tagliabue E., Menard S., Balsari A. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 2006, 176:6624-6630.
123. Gearing A.J. Targeting toll-like receptors for drug development: a summary of commercial approaches. Immunol. Cell Biol. 2007, 85:490-494.
124. Hennessy E.J., Parker A.E., O'Neill L.A. Targeting Toll-like receptors: emerging therapeutics. Nat. Rev. Drug Discov. 2010, 9:293-307.
125. Gunzer M., Riemann H., Basoglu Y., Hillmer A., Weishaupt C., Balkow S., Benninghoff B., Ernst B., Steinert M., Scholzen T., Sunderkotter C., Grabbe S. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion. Blood 2005, 106:2424-2432.